&w=3840&q=100)
Alembic Pharma receives USFDA approval for generic hypertension drug
The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement.
These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added.
Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
4 hours ago
- Hans India
UFlex Secures Indian Patent for Sustainable Waterborne Heat Seal Coating for Food and Consumer Goods Packaging
UFlex, India's largest multinational flexible packaging and solutions company, has been granted an Indian patent (No. 567989) for its latest innovation, 'Waterborne Heat Seal Coating Composition and a Process for its Preparation'. This coating has been developed as a sustainable alternative to traditional fossil-based plastic coatings, aligning with the growing demand for recyclable and environmentally responsible packaging. The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard. It is both eco-friendly and compliant with food contact regulations. This patented coating can be applied to various packaging materials, including food wraps, takeaway boxes, and blister packs for toys and personal care products. One of the key advantages of this innovation is its user-friendliness—it is a ready-to-use formulation which requires no dilution. It offers a low seal initiation temperature, excellent heat seal strength, and high hot tack strength, while meeting USFDA standards for food contact packaging. An innovative solution from UFlex's chemicals product portfolio, this development underscores the company's extensive expertise in packaging inks, water-based, solvent-less and solvent-based adhesives, and specialty UV/LED coatings. Its state-of-the-art R&D center, NABL (ISO/IEC 17025:2017), is accredited and recognised by the Department of Science and Technology, Government of India. UFlex's inks and adhesives business is focused on developing innovative solutions with sustainable technologies, customised products, food-safe and toluene-free compliant inks as per IS 15495:2020 and providing on-site support.
Business Standard
14 hours ago
- Business Standard
Dr Reddy's Lab receives EIR from USFDA for Middleburgh API facility
Dr. Reddy's Laboratories announced that its Active Pharmaceutical Ingredient (API) manufacturing facility in Middleburgh, New York, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). In a regulatory filing, the company stated that the EIR was issued following a good manufacturing practice (GMP) inspection conducted by the USFDA. The inspection outcome has been classified as Voluntary Action Indicated (VAI), and the inspection is now officially closed under 21 CFR 20.64(d)(3). This follows Dr. Reddys earlier disclosure dated 17 May 2025, in which it informed that the USFDA had completed a GMP inspection of the Middleburgh facility. The inspection took place from 12 May to 16 May 2025 (US EST) and concluded with the issuance of a Form 483 containing two observations. The company confirmed that it will address the observations within the stipulated timeline. Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddys Laboratories reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The scrip shed 0.44% to Rs 1,254 on the BSE.
Business Standard
a day ago
- Business Standard
Aarti Drugs rises after Q1 PAT jumps 62% YoY to Rs 54 cr
Aarti Drugs jumped 4.22% to Rs 544.70 after the company's consolidated net profit climbed 62.2% to Rs 53.91 crore on 6.3% increase in revenue from operations to Rs 590.51 crore in Q1 FY26 compared with Q1 FY25. Profit before tax (PBT) rose 16.2% YoY to Rs 51.11 crore in Q1 June 2025. EBITDA jumped 12% to Rs 74.4 crore in Q1 FY26 compared with Rs 66.1 crore in Q1 FY25. EBITDA margin expanded by 70 bps to 12.6% in Q1 FY26 from 11.9% posted in Q1 FY25. On segmental front, the revenue from API stood at Rs 458.2 crore (up 4% YoY), formulations was at Rs 80.3 crore (up 14% YoY), specialty & chemicals stood at Rs 33.1 crore (up 24% YoY) and intermediaries & others stood at Rs 18.9 crore (up 22% YoY) during the period under review. Adhish Patil, CFO & COO, of Aarti Drugs, said, During Q1FY26 the Company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D. For FY26, we expect Capex at around Rs 150-200 crore. The company has started trial productions at its new greenfield manufacturing facility in Sayakha, Gujarat. This plant has been set up mainly for backward integration into anti-diabetic products and their intermediates, and is expected to largely serve internal requirements. This backward integration is a key strategic step that should help improve profit margins over time and reduce the risk of input costs volatility. This project will support internal requirements for our anti-diabetic product and choline chloride, contributing to backward integration, margin improvement, and supply chain de-risking. The new greenfield Salicylic Acid plant at Tarapur is progressing well and is expected to begin contributing to the companys financials from the third quarter onwards. The company is now focused on a calibrated ramp-up of operations, with a clear roadmap to scale production to over 800 tonnes per month and further expand the installed capacity to approximately 1,600 tonnes per month by the end of FY26. Recently, the USA government has announced high tariffs on pharmaceutical products and APIs imported from countries like China. This move is aimed at reducing their dependence on Chinese suppliers. This has the potential to reshape global supply chains. While this may disrupt sourcing patterns for several players, it also opens up new opportunities for Indian API manufacturers. The company, with a recently USFDA approved API facility and established manufacturing capabilities, is strategically positioned to meet this demand shift. The commissioning of new capacity at Sayakha and Tarapur supports this readiness and enhances the Company's ability to serve regulated export markets. Our formulation subsidiary has also got USFDA approval for its Oncology facility & UKMHRA approval for our OSD facility; alongside we are on a path to develop and register new oncology dossiers across the globe which will drive the regulated market growth from FY27 onwards. Aarti Drugs was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, speciality chemicals and produces formulations with its wholly-owned subsidiary-Pinnacle Life Science.
